Diltiazem withdrawal before coronary artery bypass surgery

David R. Larach, Frederick A. Hensley, Walter Pae, Janice A. Derr, David B. Campbell

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The authors studied the effects of withdrawing oral diltiazem therapy on the subsequent course of coronary artery bypass graft surgery. Patients with severe coronary artery disease were divided into three groups using a prospective, controlled, randomized protocol. In group D (diltiazem-continuation) patients, diltiazem was administered 2.1 ± 0.1 hours (mean ± SEM) before anesthetic induction (n = 10). Group DW (diltiazem-withdrawal) patients received their final diltiazem dose 17.3 ± 2.9 hours before anesthesia (n = 10). Group R was a reference group of patients not receiving diltiazem (n = 11; not randomized). Anesthesia was induced and maintained with fentanyl and pancuronium without use of halogenated anesthetics. No clinically important differences were detected in measured hemodynamics or drug requirements. Group D patients did not have a lower systemic vascular resistance (SVR) index (P > 0.31) or mean arterial pressure (P > 0.08) compared with group DW. Also, no evidence for a diltiazem withdrawal response was found, because group DW did not have either a higher SVR index (P = 0.99) or a higher pulmonary vascular resistance index (P = 0.99) compared with group R, and no severe myocardial ischemia, coronary artery spasm, or postoperative heart block were seen. Plasma diltiazem concentrations decreased significantly during CPB (P < 0.0001), but showed overlap between groups D and DW. Plasma diltiazem concentration did not correlate significantly with simultaneous SVR. These data show the benign effects of both diltiazem administration and its acute withdrawal before coronary artery bypass surgery with high-dose fentanyl anesthesia.

Original languageEnglish (US)
Pages (from-to)688-699
Number of pages12
JournalJournal of Cardiothoracic Anesthesia
Volume3
Issue number6
DOIs
StatePublished - Jan 1 1989

Fingerprint

Diltiazem
Coronary Artery Bypass
Vascular Resistance
Anesthesia
Fentanyl
Anesthetics
Pancuronium
Heart Block
Spasm
Myocardial Ischemia
Coronary Artery Disease
Coronary Vessels
Arterial Pressure
Hemodynamics

All Science Journal Classification (ASJC) codes

  • Anesthesiology and Pain Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Larach, David R. ; Hensley, Frederick A. ; Pae, Walter ; Derr, Janice A. ; Campbell, David B. / Diltiazem withdrawal before coronary artery bypass surgery. In: Journal of Cardiothoracic Anesthesia. 1989 ; Vol. 3, No. 6. pp. 688-699.
@article{5c6f829e84df4008afd81b74869df35f,
title = "Diltiazem withdrawal before coronary artery bypass surgery",
abstract = "The authors studied the effects of withdrawing oral diltiazem therapy on the subsequent course of coronary artery bypass graft surgery. Patients with severe coronary artery disease were divided into three groups using a prospective, controlled, randomized protocol. In group D (diltiazem-continuation) patients, diltiazem was administered 2.1 ± 0.1 hours (mean ± SEM) before anesthetic induction (n = 10). Group DW (diltiazem-withdrawal) patients received their final diltiazem dose 17.3 ± 2.9 hours before anesthesia (n = 10). Group R was a reference group of patients not receiving diltiazem (n = 11; not randomized). Anesthesia was induced and maintained with fentanyl and pancuronium without use of halogenated anesthetics. No clinically important differences were detected in measured hemodynamics or drug requirements. Group D patients did not have a lower systemic vascular resistance (SVR) index (P > 0.31) or mean arterial pressure (P > 0.08) compared with group DW. Also, no evidence for a diltiazem withdrawal response was found, because group DW did not have either a higher SVR index (P = 0.99) or a higher pulmonary vascular resistance index (P = 0.99) compared with group R, and no severe myocardial ischemia, coronary artery spasm, or postoperative heart block were seen. Plasma diltiazem concentrations decreased significantly during CPB (P < 0.0001), but showed overlap between groups D and DW. Plasma diltiazem concentration did not correlate significantly with simultaneous SVR. These data show the benign effects of both diltiazem administration and its acute withdrawal before coronary artery bypass surgery with high-dose fentanyl anesthesia.",
author = "Larach, {David R.} and Hensley, {Frederick A.} and Walter Pae and Derr, {Janice A.} and Campbell, {David B.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1016/S0888-6296(89)94525-0",
language = "English (US)",
volume = "3",
pages = "688--699",
journal = "Journal of Cardiothoracic and Vascular Anesthesia",
issn = "1053-0770",
publisher = "W.B. Saunders Ltd",
number = "6",

}

Diltiazem withdrawal before coronary artery bypass surgery. / Larach, David R.; Hensley, Frederick A.; Pae, Walter; Derr, Janice A.; Campbell, David B.

In: Journal of Cardiothoracic Anesthesia, Vol. 3, No. 6, 01.01.1989, p. 688-699.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diltiazem withdrawal before coronary artery bypass surgery

AU - Larach, David R.

AU - Hensley, Frederick A.

AU - Pae, Walter

AU - Derr, Janice A.

AU - Campbell, David B.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The authors studied the effects of withdrawing oral diltiazem therapy on the subsequent course of coronary artery bypass graft surgery. Patients with severe coronary artery disease were divided into three groups using a prospective, controlled, randomized protocol. In group D (diltiazem-continuation) patients, diltiazem was administered 2.1 ± 0.1 hours (mean ± SEM) before anesthetic induction (n = 10). Group DW (diltiazem-withdrawal) patients received their final diltiazem dose 17.3 ± 2.9 hours before anesthesia (n = 10). Group R was a reference group of patients not receiving diltiazem (n = 11; not randomized). Anesthesia was induced and maintained with fentanyl and pancuronium without use of halogenated anesthetics. No clinically important differences were detected in measured hemodynamics or drug requirements. Group D patients did not have a lower systemic vascular resistance (SVR) index (P > 0.31) or mean arterial pressure (P > 0.08) compared with group DW. Also, no evidence for a diltiazem withdrawal response was found, because group DW did not have either a higher SVR index (P = 0.99) or a higher pulmonary vascular resistance index (P = 0.99) compared with group R, and no severe myocardial ischemia, coronary artery spasm, or postoperative heart block were seen. Plasma diltiazem concentrations decreased significantly during CPB (P < 0.0001), but showed overlap between groups D and DW. Plasma diltiazem concentration did not correlate significantly with simultaneous SVR. These data show the benign effects of both diltiazem administration and its acute withdrawal before coronary artery bypass surgery with high-dose fentanyl anesthesia.

AB - The authors studied the effects of withdrawing oral diltiazem therapy on the subsequent course of coronary artery bypass graft surgery. Patients with severe coronary artery disease were divided into three groups using a prospective, controlled, randomized protocol. In group D (diltiazem-continuation) patients, diltiazem was administered 2.1 ± 0.1 hours (mean ± SEM) before anesthetic induction (n = 10). Group DW (diltiazem-withdrawal) patients received their final diltiazem dose 17.3 ± 2.9 hours before anesthesia (n = 10). Group R was a reference group of patients not receiving diltiazem (n = 11; not randomized). Anesthesia was induced and maintained with fentanyl and pancuronium without use of halogenated anesthetics. No clinically important differences were detected in measured hemodynamics or drug requirements. Group D patients did not have a lower systemic vascular resistance (SVR) index (P > 0.31) or mean arterial pressure (P > 0.08) compared with group DW. Also, no evidence for a diltiazem withdrawal response was found, because group DW did not have either a higher SVR index (P = 0.99) or a higher pulmonary vascular resistance index (P = 0.99) compared with group R, and no severe myocardial ischemia, coronary artery spasm, or postoperative heart block were seen. Plasma diltiazem concentrations decreased significantly during CPB (P < 0.0001), but showed overlap between groups D and DW. Plasma diltiazem concentration did not correlate significantly with simultaneous SVR. These data show the benign effects of both diltiazem administration and its acute withdrawal before coronary artery bypass surgery with high-dose fentanyl anesthesia.

UR - http://www.scopus.com/inward/record.url?scp=0024785469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024785469&partnerID=8YFLogxK

U2 - 10.1016/S0888-6296(89)94525-0

DO - 10.1016/S0888-6296(89)94525-0

M3 - Article

C2 - 2577711

AN - SCOPUS:0024785469

VL - 3

SP - 688

EP - 699

JO - Journal of Cardiothoracic and Vascular Anesthesia

JF - Journal of Cardiothoracic and Vascular Anesthesia

SN - 1053-0770

IS - 6

ER -